- 专利标题： Combinations of artemisinins, BCL-2 inhibitors, and kinase inhibitors for cancer treatment
-
申请号： US16670218申请日： 2019-10-31
-
公开(公告)号： US11554105B2公开(公告)日： 2023-01-17
- 发明人: Curt I. Civin , Blake S. Moses
- 申请人： UNIVERSITY OF MARYLAND, BALTIMORE
- 申请人地址： US MD Baltimore
- 专利权人： UNIVERSITY OF MARYLAND, BALTIMORE
- 当前专利权人： UNIVERSITY OF MARYLAND, BALTIMORE
- 当前专利权人地址： US MD Baltimore
- 代理机构： Wenderoth, Lind & Ponack, L.L.P.
- 主分类号： A61K31/343
- IPC分类号： A61K31/343 ; A61P35/02 ; A61K45/06
摘要：
Methods of treating cancer, such as leukemia, via administration of therapeutically effective amounts of artemisinins and one or more additional therapeutic agents are detailed herein. The artemisinins include artesunate, dihydroartemisinin, artemether, arteether, artelinate, ART-631, and ART-838. The one or more additional therapeutic agents include BCL-2 inhibitors such as ABT-199, ABT-263, and ABT-737; kinase inhibitors such as lestaurtinib, midostaurin, and sorafenib; and anti-neoplastic agents such as cytarabine, doxorubicin, etoposide, cyclophosphamide, triplotide, vinorelbine, cisplatin, and rituximab.
信息查询
IPC分类:
